

Global Hemoglobinopathies Market Size study, by Type (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants), by Diagnosis, by Therapy, and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/GCD002F6721EEN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,750.00 (Single User License)

ID: GCD002F6721EEN

Abstracts

The Global Hemoglobinopathies Market is valued at approximately USD 9.32 billion in 2023 and is anticipated to expand at a dynamic CAGR of over 12.60% during the forecast period 2024–2032. Hemoglobinopathies represent a group of inherited blood disorders characterized by abnormalities in the structure or production of hemoglobin. Among the most prevalent forms are sickle cell disease and thalassemia, both of which significantly impact morbidity and mortality rates worldwide. These conditions have transitioned from neglected rare diseases to global health priorities due to increasing awareness, genomic advancements, and growing healthcare investments. With diagnostic innovations enabling early detection and therapeutic breakthroughs enhancing life expectancy, the hemoglobinopathies landscape is undergoing transformative growth.

As scientific interest in rare diseases surges, cutting-edge genomic tools such as next-generation sequencing and CRISPR-Cas9 gene editing are being deployed to not only diagnose but potentially cure hemoglobinopathies. Major pharmaceutical companies, driven by lucrative orphan drug incentives and an urgency to reduce disease burden in high-prevalence regions, are scaling R&D pipelines to develop curative gene therapies, biologics, and personalized medicines. Furthermore, the momentum of newborn screening programs, particularly in the United States, Europe, and emerging economies, continues to boost early intervention efforts and widen the therapeutic window for at-risk populations. Despite these advancements, limited access to quality care in low-resource settings and high treatment costs remain considerable bottlenecks.

The therapy landscape is rapidly diversifying, moving beyond conventional transfusions and chelation therapies toward curative intent strategies such as stem cell transplants and gene therapies. Global collaborations between biopharmaceutical innovators and non-profit consortia are strengthening clinical trial networks across endemic regions, bringing breakthrough therapies closer to approval and patient access. Additionally, the growing emphasis on companion diagnostics and disease-modifying agents is changing how hemoglobinopathies are managed—transitioning from symptomatic treatment to long-term disease control and even potential eradication.

The increasing global prevalence of hemoglobinopathies, especially in sub-Saharan Africa, South Asia, and the Mediterranean, is triggering strong demand for scalable screening infrastructure and therapeutic access. Governments and global health organizations are prioritizing these diseases under rare and neglected disorders programs, unlocking new funding opportunities for both diagnostics and drug developers. Moreover, emerging trends such as digital therapeutics, remote patient monitoring, and value-based care models are being adopted to ensure compliance, reduce healthcare costs, and improve patient outcomes in chronic care scenarios.

Regionally, North America holds a leading position in the hemoglobinopathies market, backed by robust healthcare systems, advanced genomics laboratories, and significant public-private partnerships. Europe is closely trailing, driven by growing immigrant populations from high-prevalence regions and rising government initiatives in rare disease registries. Meanwhile, Asia Pacific is poised to experience the fastest growth, spurred by a vast patient population, increasing healthcare expenditure, and the rapid proliferation of molecular diagnostic technologies in countries like India and China. Latin America and the Middle East & Africa are also gradually establishing clinical infrastructure and awareness campaigns to manage the increasing burden of these genetic conditions.

Major market player included in this report are:

Novartis AG

Bluebird Bio, Inc.

Pfizer Inc.

Vertex Pharmaceuticals Incorporated

CRISPR Therapeutics

Sangamo Therapeutics

Bristol-Myers Squibb Company

Emmaus Life Sciences, Inc.

Global Blood Therapeutics, Inc.

Editas Medicine, Inc.

Accelaron Pharma, Inc.

Bioverativ Inc.

Alnylam Pharmaceuticals

Sanofi S.A.

Agios Pharmaceuticals, Inc.

The detailed segments and sub-segment of the market are explained below:

By Type

Thalassemia

Sickle Cell Disease

Other Hemoglobin (Hb) Variants

By Diagnosis

Complete Blood Count (CBC)

Hemoglobin Electrophoresis

Genetic Testing

Prenatal Testing

Others

By Therapy

Blood Transfusions

Iron Chelation Therapy

Stem Cell Transplantation

Gene Therapy

Pharmacological Agents

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL HEMOGLOBINOPATHIES MARKET EXECUTIVE SUMMARY

- 1.1. Global Hemoglobinopathies Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Type
 - 1.3.2. By Diagnosis
 - 1.3.3. By Therapy
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL HEMOGLOBINOPATHIES MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Payer & Patient Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Prevalence of Inherited Blood Disorders
 - 2.3.4.2. Advances in Genomic Diagnostics
 - 2.3.4.3. Newborn Screening Initiatives
 - 2.3.4.4. Treatment Access and Reimbursement
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL HEMOGLOBINOPATHIES MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Rising Prevalence of Thalassemia and Sickle Cell Disease
- 3.1.2. Technological Advancements in Genetic Testing
- 3.1.3. Expansion of Newborn Screening Programs

3.2. Market Challenges

- 3.2.1. High Cost of Curative Therapies
- 3.2.2. Limited Access in Low-Resource Settings

3.3. Market Opportunities

- 3.3.1. Gene Therapy and Genome Editing Pipelines
- 3.3.2. Digital Therapeutics and Remote Monitoring
- 3.3.3. Growth in Emerging Asia Pacific and Africa Markets

CHAPTER 4. GLOBAL HEMOGLOBINOPATHIES MARKET INDUSTRY ANALYSIS

4.1. Porter's Five Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Five Forces
- 4.1.7. Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunities

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspectives

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE & FORECASTS BY TYPE 2022–2032

5.1. Segment Dashboard

5.2. Global Hemoglobinopathies Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)

- 5.2.1. Thalassemia
- 5.2.2. Sickle Cell Disease
- 5.2.3. Other Hemoglobin (Hb) Variants

CHAPTER 6. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE & FORECASTS BY DIAGNOSIS 2022–2032

6.1. Segment Dashboard

6.2. Global Hemoglobinopathies Market: Diagnosis Revenue Trend Analysis, 2022 & 2032 (USD Billion)

- 6.2.1. Complete Blood Count (CBC)
- 6.2.2. Hemoglobin Electrophoresis
- 6.2.3. Genetic Testing
- 6.2.4. Prenatal Testing
- 6.2.5. Others

CHAPTER 7. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE & FORECASTS BY THERAPY 2022–2032

7.1. Segment Dashboard

7.2. Global Hemoglobinopathies Market: Therapy Revenue Trend Analysis, 2022 & 2032 (USD Billion)

- 7.2.1. Blood Transfusions
- 7.2.2. Iron Chelation Therapy
- 7.2.3. Stem Cell Transplantation
- 7.2.4. Gene Therapy
- 7.2.5. Pharmacological Agents
- 7.2.6. Others

CHAPTER 8. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE & FORECASTS BY REGION 2022–2032

8.1. North America

- 8.1.1. U.S.
 - 8.1.1.1. Type breakdown size & forecasts, 2022–2032
 - 8.1.1.2. Diagnosis breakdown size & forecasts, 2022–2032
- 8.1.2. Canada

- 8.2. Europe
 - 8.2.1. UK
 - 8.2.2. Germany
 - 8.2.3. France
 - 8.2.4. Spain
 - 8.2.5. Italy
 - 8.2.6. Rest of Europe
- 8.3. Asia Pacific
 - 8.3.1. China
 - 8.3.2. India
 - 8.3.3. Japan
 - 8.3.4. Australia
 - 8.3.5. South Korea
 - 8.3.6. Rest of Asia Pacific
- 8.4. Latin America
 - 8.4.1. Brazil
 - 8.4.2. Mexico
 - 8.4.3. Rest of Latin America
- 8.5. Middle East & Africa
 - 8.5.1. Saudi Arabia
 - 8.5.2. South Africa
 - 8.5.3. Rest of Middle East & Africa

CHAPTER 9. COMPETITIVE INTELLIGENCE

- 9.1. Key Company SWOT Analysis
 - 9.1.1. Novartis AG
 - 9.1.2. Bluebird Bio, Inc.
 - 9.1.3. Pfizer Inc.
- 9.2. Top Market Strategies
- 9.3. Company Profiles
 - 9.3.1. Novartis AG
 - 9.3.1.1. Key Information
 - 9.3.1.2. Overview
 - 9.3.1.3. Financial (Subject to Data Availability)
 - 9.3.1.4. Product Summary
 - 9.3.1.5. Market Strategies
 - 9.3.2. Bluebird Bio, Inc.
 - 9.3.3. Pfizer Inc.

- 9.3.4. Vertex Pharmaceuticals Incorporated
- 9.3.5. CRISPR Therapeutics
- 9.3.6. Sangamo Therapeutics
- 9.3.7. Bristol-Myers Squibb Company
- 9.3.8. Emmaus Life Sciences, Inc.
- 9.3.9. Global Blood Therapeutics, Inc.
- 9.3.10. Editas Medicine, Inc.
- 9.3.11. Acceleron Pharma, Inc.
- 9.3.12. Bioverativ Inc.
- 9.3.13. Alnylam Pharmaceuticals
- 9.3.14. Sanofi S.A.
- 9.3.15. Agios Pharmaceuticals, Inc.

CHAPTER 10. RESEARCH PROCESS

- 10.1. Research Process
 - 10.1.1. Data Mining
 - 10.1.2. Analysis
 - 10.1.3. Market Estimation
 - 10.1.4. Validation
 - 10.1.5. Publishing
- 10.2. Research Attributes

I would like to order

Product name: Global Hemoglobinopathies Market Size study, by Type (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants), by Diagnosis, by Therapy, and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/GCD002F6721EEN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GCD002F6721EEN.html>